Aratana Therapeutics, Inc. (NASDAQ:PETX) – Equities research analysts at William Blair lowered their FY2020 EPS estimates for shares of Aratana Therapeutics in a report issued on Monday. William Blair analyst J. Kreger now expects that the biopharmaceutical company will post earnings per share of $0.83 for the year, down from their prior forecast of $0.90.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 52.00%. The firm had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $4.50 million. During the same period in the prior year, the company earned $0.61 EPS. The firm’s revenue was down 86.4% on a year-over-year basis. COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/aratana-therapeutics-inc-petx-to-post-fy2020-earnings-of-0-83-per-share-william-blair-forecasts.html.

A number of other brokerages also recently weighed in on PETX. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. ValuEngine raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 25th. BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Jefferies Group LLC set a $8.00 price target on shares of Aratana Therapeutics and gave the company a “buy” rating in a report on Friday. Finally, Stifel Nicolaus reduced their price target on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Shares of Aratana Therapeutics (NASDAQ PETX) traded down 2.40% during mid-day trading on Tuesday, reaching $6.11. 191,120 shares of the company were exchanged. The company’s market capitalization is $231.92 million. The firm’s 50-day moving average is $7.07 and its 200-day moving average is $6.46. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $10.73.

Several institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its position in Aratana Therapeutics by 7.9% in the second quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares during the last quarter. American International Group Inc. increased its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,354 shares during the last quarter. Geneva Advisors LLC increased its position in Aratana Therapeutics by 3.7% in the second quarter. Geneva Advisors LLC now owns 80,118 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 2,830 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 3,883 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC increased its position in Aratana Therapeutics by 8.3% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 65,000 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 5,000 shares during the last quarter. 67.85% of the stock is owned by institutional investors.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.